Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

In this multicenter, placebo-controlled trial involving statin-treated patients with hypertriglyceridemia, the risk of ischemic events, including cardiovascular death, was significantly lower with 2 g of icosapent ethyl twice daily than with placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-01, Vol.380 (1), p.11-22
Hauptverfasser:	Bhatt, Deepak L, Steg, P. Gabriel, Miller, Michael, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Doyle, Ralph T, Juliano, Rebecca A, Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Ballantyne, Christie M
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angina Angina pectoris Cardiovascular diseases Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cerebral infarction Cholesterol Death Diabetes mellitus Disease prevention Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Eicosapentaenoic acid Eicosapentaenoic Acid - analogs & derivatives Eicosapentaenoic Acid - therapeutic use Female Fibrillation Follow-Up Studies Health risk assessment Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypertriglyceridemia Hypertriglyceridemia - drug therapy Incidence Ischemia Kaplan-Meier Estimate Male Middle Aged Myocardial infarction Platelet Aggregation Inhibitors - therapeutic use Risk Factors Secondary Prevention Statins Stroke Triglycerides - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this multicenter, placebo-controlled trial involving statin-treated patients with hypertriglyceridemia, the risk of ischemic events, including cardiovascular death, was significantly lower with 2 g of icosapent ethyl twice daily than with placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1812792